The Historical Evolution of Nanjing Tongrentang

20 1210.9,12, Nanjing pharmaceutical announced that it would transfer 40% equity of Nanjing pharmaceutical international health industry co., ltd. (hereinafter referred to as Nanyao international) to Jiangsu Hongshi technology industry co., ltd. (hereinafter referred to as Hongshi technology) for 83.384 million yuan.

Since then, Nanjing Pharmaceutical will no longer hold the equity of Nanyao International, and all the medical assets of Nanyao International will fall into Hongshi Technology. For Nanyao International, which was established in June, 5438+February, 2009, it took less than three years from state ownership to privatization.

Nanjing Pharmaceutical announced that the reason for transferring the equity of Nanyao International was that the company formally signed the Strategic Cooperation Agreement with Nanjing Pharmaceutical Group and AllianceBootsHoldingsLimited (hereinafter referred to as United Capital) on September 6 this year.

According to the Catalogue of Foreign Investment Industries jointly issued by the National Development and Reform Commission and the Ministry of Commerce, the company needs to divest some industries that currently prohibit and restrict foreign investment.

Nanjing Tongrentang Pharmaceutical Co., Ltd. (hereinafter referred to as Nanjing Tongrentang), Nanjing Tongrentang Huangshan Refined Pharmaceutical Co., Ltd. (hereinafter referred to as Tongrentang Huangshan) and Nanjing Tongrentang Hongze Chinese Herbal Medicine Technology Co., Ltd. (hereinafter referred to as Tongrentang Hongze), which are controlled by Nanyao International, are related to the processing technology application of Chinese herbal pieces and the production of secret Chinese patent medicines, and belong to industries where foreign investment is prohibited by policies. The transfer of 40% equity of Nanyao International held by Nanjing Pharmaceutical will help promote the cooperation between the two parties.

Nanjing Pharmaceutical holds 40% equity of Nanyao International, and Hongshi Technology holds 60%. According to the principle of priority transfer, Hongshi Technology naturally became the transferee of 40% equity of Nanyao International.

The six holding subsidiaries transferred this time are Nanjing Tongrentang 100% equity, Tongrentang Huangshan 58.96% equity, Tongrentang Hongze 87% equity, Sichuan Nanyao Chuanjiang Pharmaceutical Co., Ltd. 93.6% equity, Xuzhou Pharmaceutical Co., Ltd. 8 1.07% equity and Nanjing Life Energy Technology Development Co., Ltd. 55% equity.

After the transfer is completed, Nanjing Pharmaceutical only holds 5% equity of Xuzhou Pharmaceutical, and no longer holds equity of the other five subsidiaries. More notably, in this transfer, the transfer price of Tongrentang Huangshan and Tongrentang Hongze is only 1 yuan.